<p><strong> </strong><strong>Clinicians should assess if a newly diagnosed mHSPC patient is experiencing symptoms from metastatic disease at the time of presentation to guide discussions of prognosis and further disease management. (<em>Moderate Recommendation; Evidence Level: Grade B</em>)</strong></p>
Discussion
Discussion
<p>Symptoms in mHSPC have been shown to have prognostic value. In addition, understanding cancer-related symptoms is key to optimizing pain and other symptom management in addition to anti-cancer therapy. In an analysis of patients in the SWOG 8894 trial, presence of bone pain (adjusted OR=2.61; 95% CI: 1.66 to 4.12) was among the factors associated with poorer 10-year survival.<sup>77</sup></p>